search icon
imab-img

I-Mab, Common Stock

IMAB

NMQ

$1.375

+$0.11

(8.73%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$85.74M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
241.03K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.13
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.59 L
$2 H
$1.375

About I-Mab, Common Stock

I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMABSectorS&P500
1-Week Return20%1.39%1.18%
1-Month Return55.17%-4.97%6.44%
3-Month Return36.07%-11.13%-0.73%
6-Month Return35.16%-10.21%-2.01%
1-Year Return-28.81%-6.5%12.12%
3-Year Return-85.52%0.1%42.84%
5-Year Return-94.95%28.49%93.86%
10-Year Return-89.92%76.62%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.54B88.03M(221.56M)27.64M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":5.71,"profit":true},{"date":"2022-12-31","value":-14.36,"profit":false},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-46.43M27.24M--[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":58.66,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit1.54B41.59M(248.80M)27.64M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.7,"profit":true},{"date":"2022-12-31","value":-16.13,"profit":false},{"date":"2023-12-31","value":1.79,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%47.25%112.29%100.00%-[{"date":"2020-12-31","value":89.05,"profit":true},{"date":"2021-12-31","value":42.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.05,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses1.08B2.40B2.28B201.20M50.15M[{"date":"2020-12-31","value":45.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.29,"profit":true},{"date":"2023-12-31","value":8.39,"profit":true},{"date":"2024-12-31","value":2.09,"profit":true}]
Operating Income155.57M(2.07B)(1.97B)(1.24B)(50.15M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1331.43,"profit":false},{"date":"2022-12-31","value":-1265.97,"profit":false},{"date":"2023-12-31","value":-794.51,"profit":false},{"date":"2024-12-31","value":-32.24,"profit":false}]
Total Non-Operating Income/Expense350.85M(242.06M)(510.25M)(178.65M)457.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-68.99,"profit":false},{"date":"2022-12-31","value":-145.43,"profit":false},{"date":"2023-12-31","value":-50.92,"profit":false},{"date":"2024-12-31","value":0.13,"profit":true}]
Pre-Tax Income483.15M(2.33B)(2.51B)(1.47B)(49.70M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-483.23,"profit":false},{"date":"2022-12-31","value":-518.81,"profit":false},{"date":"2023-12-31","value":-303.36,"profit":false},{"date":"2024-12-31","value":-10.29,"profit":false}]
Income Taxes12.23M3.15M697.00K(1.26B)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":25.79,"profit":true},{"date":"2022-12-31","value":5.7,"profit":true},{"date":"2023-12-31","value":-10292.91,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes470.92M(2.34B)(2.51B)(206.77M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-496.45,"profit":false},{"date":"2022-12-31","value":-532.44,"profit":false},{"date":"2023-12-31","value":-43.91,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations470.92M(2.33B)(2.41B)(1.47B)(49.70M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-495.11,"profit":false},{"date":"2022-12-31","value":-512.16,"profit":false},{"date":"2023-12-31","value":-311.24,"profit":false},{"date":"2024-12-31","value":-10.55,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income470.92M(2.33B)(2.51B)(1.47B)(22.23M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-495.11,"profit":false},{"date":"2022-12-31","value":-532.44,"profit":false},{"date":"2023-12-31","value":-311.24,"profit":false},{"date":"2024-12-31","value":-4.72,"profit":false}]
EPS (Diluted)1.02(1.59)(2.92)-(0.57)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-155.66,"profit":false},{"date":"2022-12-31","value":-285.51,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-55.39,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMAB
Cash Ratio 20.51
Current Ratio 20.90

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMAB
ROA (LTM) -11.05%
ROE (LTM) -19.70%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMAB
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMAB
Trailing PE NM
Forward PE NM
P/S (TTM) 25.39
P/B 0.52
EV/R 0.99
EV/Ebitda 0.14

FAQs

What is I-Mab share price today?

I-Mab (IMAB) share price today is $1.375

Can Indians buy I-Mab shares?

Yes, Indians can buy shares of I-Mab (IMAB) on Vested. To buy I-Mab from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of I-Mab be purchased?

Yes, you can purchase fractional shares of I-Mab (IMAB) via the Vested app. You can start investing in I-Mab (IMAB) with a minimum investment of $1.

How to invest in I-Mab shares from India?

You can invest in shares of I-Mab (IMAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in I-Mab shares
What is I-Mab 52-week high and low stock price?

The 52-week high price of I-Mab (IMAB) is $2. The 52-week low price of I-Mab (IMAB) is $0.59.

What is I-Mab price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of I-Mab (IMAB) is 0.52

What is the Market Cap of I-Mab?

The market capitalization of I-Mab (IMAB) is $85.74M

What is I-Mab’s stock symbol?

The stock symbol (or ticker) of I-Mab is IMAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top